# China NMPA Drug Inspection - Bozhou City Traditional Chinese Medicine Slices Factory - Stir-fried Atractylodes lancea

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/bozhou-city-traditional-chinese-medicine-slices-factory/9cd2ab29-ba8b-4b67-b176-c027b867498a/
Source feed: China

> China NMPA drug inspection for Bozhou City Traditional Chinese Medicine Slices Factory published June 29, 2018. Drug: Stir-fried Atractylodes lancea. On June 29, 2018, the Henan Provincial Food and Drug Administration announced findings from inspections that revealed fo

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Henan Provincial Food and Drug Administration regarding four batches of substandard drugs (Issue No. 7, 2018)
- Company Name: Bozhou City Traditional Chinese Medicine Slices Factory
- Publication Date: 2018-06-29
- Drug Name: Stir-fried Atractylodes lancea
- Inspection Finding: The substandard item was content, which is suspected of being counterfeit.
- Action Taken: The relevant food and drug regulatory authorities have been instructed to take necessary risk control measures such as sealing up, seizing, and suspending the sale of substandard drugs, and to investigate and punish the units that source the samples in accordance with the law.
- Summary: On June 29, 2018, the Henan Provincial Food and Drug Administration announced findings from inspections that revealed four batches of substandard drugs from three companies. Anhui Yishengyuan Traditional Chinese Medicine Pieces Technology Co., Ltd. was cited for Atractylodes lancea (batch 160601) having substandard moisture content. Tianma (Anhui) Traditional Chinese Medicine Pieces Technology Co., Ltd. produced Atractylodes lancea stir-fried with wheat bran (batch 150401) with substandard content. Products from Bozhou City Traditional Chinese Medicine Slices Factory, specifically stir-fried Atractylodes lancea and Atractylodes lancea (both batch 170223) sold by Kaifeng Furui Pharmaceutical Retail Co., Ltd., were also found to have substandard content and were suspected of being counterfeit.

The regulatory framework for these findings relies on quality standards detailed in the Chinese Pharmacopoeia (2010 and 2015 editions), under the broader national oversight of the National Medical Products Administration (NMPA). As a result of these violations, the Henan Provincial Food and Drug Administration mandated immediate risk control measures, including sealing, seizing, and suspending the sale of the non-compliant drugs. Additionally, regulatory departments were instructed to conduct thorough investigations and impose legal penalties on the responsible manufacturing and retail entities.

Company: https://www.globalkeysolutions.net/companies/bozhou-city-traditional-chinese-medicine-slices-factory/d4ad36c1-e429-4c61-ac4f-0718fce0def4/